CliffBio
small molecule

NINLARO

IXAZOMIB CITRATE

Loss of exclusivityNovember 2029latest FDA-listed patent expiry
CompanyTAKEDA PHARMACEUTICALS USA INC

Drug detail

Brand nameNINLARO
Active ingredientIXAZOMIB CITRATE
StrengthEQ 3MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2015
Marketing statusRX

Listed patents

PatentExpiresType
7442830November 2029substance, product
9175017June 2029use U-2434
8859504June 2029substance, product
8530694August 2027substance, product
8871745August 2027use U-2434
7687662August 2027substance, product
8003819August 2027substance, product

More from TAKEDA PHARMACEUTICALS USA INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

NINLARO patent cliff — loss of exclusivity November 2029 | CliffBio